title: In vitro suppressive effect of aflatoxin B1 on murine peritoneal macrophage functions.
abstract: We examined the immunosuppressive effects of aflatoxin B1 (AFB1), a toxic compound produced by the Aspergillus flavus, on murine peritoneal macrophages after in vitro pre-exposure. When thioglycollate-elicited macrophages pre-exposed to AFB1 were stimulated with lipopolysaccharide (LPS), antitumor activity induced by LPS was suppressed by 10 and 50 microM AFB1. In addition, the production of reactive intermediates including nitric oxide (NO), superoxide anion and hydrogen peroxide which have been known to be implicated in macrophage-mediated cytotoxicity, was decreased by AFB1 pretreatment in a dose-dependent manner. We also determined whether the macrophage-mediated cytokine production was altered by AFB1 in vitro pretreatment. AFB1 markedly inhibited TNF-alpha interleukin-1 (IL-1) and IL-6 production by LPS-stimulated macrophages. Taken together, these data indicate that AFB1 inhibits the killing ability of murine macrophages, decreases various secretory molecules in those cells and the macrophages would be one of many systems affected by AFB1.
authors.affiliation: College of Pharmacy, Sung Kyun Kwan University, Suwon City, South Korea.
authors.forename: E Y
authors.initials: EY
authors.lastname: Moon
authors.forename: D K
authors.initials: DK
authors.lastname: Rhee
authors.forename: S
authors.initials: S
authors.lastname: Pyo
mesh_terms: D016604:Aflatoxin B1 / Q000633:toxicity*; D000818:Animals; D002273:Carcinogens / Q000633:toxicity*; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D007166:Immunosuppressive Agents / Q000633:toxicity*; D007375:Interleukin-1 / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D015850:Interleukin-6 / Q000096:biosynthesis; D008262:Macrophage Activation / Q000187:drug effects / Q000502:physiology; D017737:Macrophages, Peritoneal / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D008297:Male; D008546:Melanoma, Experimental / Q000276:immunology / Q000628:therapy; D051379:Mice; D009569:Nitric Oxide / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D017382:Reactive Oxygen Species / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D000093242:Interleukin-6 Inhibitors
chemical_list: D016604:Aflatoxin B1; D002273:Carcinogens; D007166:Immunosuppressive Agents; D007375:Interleukin-1; D015850:Interleukin-6; D009569:Nitric Oxide; D017382:Reactive Oxygen Species; D014409:Tumor Necrosis Factor-alpha; D000093242:Interleukin-6 Inhibitors